{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:00:32Z","timestamp":1791939632538,"version":"4.3.4"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008065","name":"GRA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mercer University School of Medicine"},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7142026"],"award-info":[{"award-number":["7142026"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.cca.2016.11.010","type":"journal-article","created":{"date-parts":[[2016,11,9]],"date-time":"2016-11-09T13:02:59Z","timestamp":1478696579000},"page":"155-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Pathologic significance of SET\/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)"],"prefix":"10.1016","volume":"464","author":[{"given":"Shi-Wen","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siliang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoqing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2016.11.010_bb0005","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1128\/MCB.12.8.3346","article-title":"Can, a putative oncogene associated with myeloid leukemogenesis, may be activated by fusion of its 3\u2032 half to different genes: characterization of the set gene","volume":"12","author":"von Lindern","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cca.2016.11.010_bb0010","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.emboj.7601518","article-title":"Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET","volume":"26","author":"ten Klooster","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.cca.2016.11.010_bb0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/(SICI)1097-4644(19990701)74:1<119::AID-JCB13>3.0.CO;2-7","article-title":"Expression of SET is modulated as a function of cell proliferation","volume":"74","author":"Shin","year":"1999","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.cca.2016.11.010_bb0020","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1074\/jbc.M207497200","article-title":"The SET protein regulates G2\/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity","volume":"278","author":"Canela","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.11.010_bb0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/1471-2202-15-82","article-title":"Cytoplasmic SET induces tau hyperphosphorylation through a decrease of methylated phosphatase 2A","volume":"15","author":"Chasseigneaux","year":"2014","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.cca.2016.11.010_bb0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/104454901753340604","article-title":"Developmental gonadal expression of the transcription factor SET and its target gene, P450c17 (17alpha-hydroxylase\/c17,20 lyase)","volume":"20","author":"Zhang","year":"2001","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.cca.2016.11.010_bb0035","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2091-10-10","article-title":"Identification of distinct SET\/TAF-Ibeta domains required for core histone binding and quantitative characterisation of the interaction","volume":"10","author":"Karetsou","year":"2009","journal-title":"BMC Biochem."},{"key":"10.1016\/j.cca.2016.11.010_bb0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/nar\/gkr614","article-title":"Inhibition of p53 acetylation by INHAT subunit SET\/TAF-Ibeta represses p53 activity","volume":"40","author":"Kim","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cca.2016.11.010_bb0045","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/excr.1997.3930","article-title":"Cellular localization and expression of template-activating factor I in different cell types","volume":"240","author":"Nagata","year":"1998","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.cca.2016.11.010_bb0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00401-011-0908-x","article-title":"An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide","volume":"123","author":"Bolognin","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cca.2016.11.010_bb0055","doi-asserted-by":"crossref","first-page":"17495","DOI":"10.1074\/jbc.M112.446070","article-title":"Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease","volume":"288","author":"Basurto-Islas","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.11.010_bb0060","doi-asserted-by":"crossref","first-page":"11059","DOI":"10.1074\/jbc.271.19.11059","article-title":"The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A","volume":"271","author":"Li","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.11.010_bb0065","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00401-013-1175-9","article-title":"Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection","volume":"127","author":"Wang","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cca.2016.11.010_bb0070","doi-asserted-by":"crossref","first-page":"27677","DOI":"10.1074\/jbc.M114.565358","article-title":"Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau","volume":"289","author":"Arif","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.11.010_bb0075","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.1038\/srep15182","article-title":"Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET - PP2A signaling axis","volume":"5","author":"Hu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2016.11.010_bb0080","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1073\/pnas.1317630111","article-title":"Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer","volume":"111","author":"Janghorban","year":"2014","journal-title":"P. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cca.2016.11.010_bb0085","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/ijc.22054","article-title":"SET complex in serous epithelial ovarian cancer","volume":"119","author":"Ouellet","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cca.2016.11.010_bb0090","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1541-7786.MCR-13-0542","article-title":"Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer","volume":"12","author":"Farrell","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cca.2016.11.010_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1476-4598-13-32","article-title":"Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models","volume":"13","author":"Sobral","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cca.2016.11.010_bb0100","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/emmm.201201283","article-title":"Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis","volume":"5","author":"Saddoughi","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.cca.2016.11.010_bb0105","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1038\/onc.2010.622","article-title":"Targeting SET\/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy","volume":"30","author":"Switzer","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.cca.2016.11.010_bb0110","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1677\/jme.0.0330059","article-title":"The molecular characteristics of polycystic ovary syndrome (PCOS) ovary defined by human ovary cDNA microarray","volume":"33","author":"Diao","year":"2004","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1477-7827-11-9","article-title":"SET protein up-regulated testosterone production in the cultured preantral follicles","volume":"11","author":"Xu","year":"2013","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0120","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.mce.2013.04.012","article-title":"SET\/PP2A system regulates androgen production in ovarian follicles in vitro","volume":"374","author":"Gao","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0125","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1073\/pnas.92.10.4279","article-title":"Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2016.11.010_bb0130","first-page":"81","article-title":"Analysis of nucleo-cytoplasmic shuttling of the proto-oncogene SET\/I2PP2A","volume":"81","author":"Lam","year":"2012","journal-title":"Cytometry A"},{"key":"10.1016\/j.cca.2016.11.010_bb0135","doi-asserted-by":"crossref","first-page":"17064","DOI":"10.1074\/jbc.270.29.17064","article-title":"Cyclin-dependent kinase site-regulated signal-dependent nuclear localization of the SW15 yeast transcription factor in mammalian cells","volume":"270","author":"Jans","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.11.010_bb0140","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/0092-8674(84)90457-4","article-title":"A short amino acid sequence able to specify nuclear location","volume":"39","author":"Kalderon","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.cca.2016.11.010_bb0145","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.neurobiolaging.2012.12.025","article-title":"Ser9 phosphorylation causes cytoplasmic detention of I2PP2A\/SET in Alzheimer disease","volume":"34","author":"Yu","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2016.11.010_bb0150","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1093\/hmg\/7.12.1947","article-title":"The Treacher Collins syndrome (TCOF1) gene product, treacle, is targeted to the nucleolus by signals in its C-terminus","volume":"7","author":"Winokur","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cca.2016.11.010_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051242","article-title":"Phosphorylation of SET protein at Ser171 by protein kinase D2 diminishes its inhibitory effect on protein phosphatase 2A","volume":"7","author":"Irie","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2016.11.010_bb0160","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/pmic.200600458","article-title":"Proteomic analysis of SET-binding proteins","volume":"7","author":"Vera","year":"2007","journal-title":"Proteomics"},{"key":"10.1016\/j.cca.2016.11.010_bb0165","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.febslet.2012.11.013","article-title":"Cytoplasmic targeting of the proto-oncogene SET promotes cell spreading and migration","volume":"587","author":"Lam","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cca.2016.11.010_bb0170","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","article-title":"Polycystic ovary syndrome","volume":"352","author":"Ehrmann","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2016.11.010_bb0175","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/rep.0.1230023","article-title":"Survival factors regulating ovarian apoptosis \u2013 dependence on follicle differentiation","volume":"123","author":"Markstrom","year":"2002","journal-title":"Reproduction"},{"key":"10.1016\/j.cca.2016.11.010_bb0180","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1210\/endo-122-6-2780","article-title":"Factors influencing follicle-stimulating hormone-responsive steroidogenesis in marmoset granulosa cells: effects of androgens and the stage of follicular maturity","volume":"122","author":"Harlow","year":"1988","journal-title":"Endocrinology"},{"key":"10.1016\/j.cca.2016.11.010_bb0185","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0889-8529(05)70070-0","article-title":"Ovarian and adrenal function in polycystic ovary syndrome","volume":"28","author":"Rosenfield","year":"1999","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.cca.2016.11.010_bb0190","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/humupd\/dmi025","article-title":"Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth","volume":"11","author":"Diamanti-Kandarakis","year":"2005","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.cca.2016.11.010_bb0195","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0015-0282(16)53510-9","article-title":"Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome","volume":"53","author":"Rosenfield","year":"1990","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.cca.2016.11.010_bb0200","first-page":"274","article-title":"Hyperandrogenism: clinical aspects, investigation and treatment","volume":"54","author":"Beckers","year":"1999","journal-title":"Rev. Med. Liege"},{"key":"10.1016\/j.cca.2016.11.010_bb0205","doi-asserted-by":"crossref","DOI":"10.2174\/1871530316666160201145934","article-title":"Metabolic Basis of Polycystic Ovarian Syndrome; indications for biochemical screening","author":"Omabe","year":"2016","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.cca.2016.11.010_bb0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00006254-200005000-00026","article-title":"Hyperinsulinism and its interaction with hyperandrogenism in polycystic ovary syndrome","volume":"55","author":"Sozen","year":"2000","journal-title":"Obstet. Gynecol. Surv."},{"key":"10.1016\/j.cca.2016.11.010_bb0215","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2007-1016297","article-title":"Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome","volume":"15","author":"Barnes","year":"1997","journal-title":"Semin. Reprod. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1477-7827-4-17","article-title":"Contributions of androgen and estrogen to fetal programming of ovarian dysfunction","volume":"4","author":"Abbott","year":"2006","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0225","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1210\/en.2014-1887","article-title":"Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization","volume":"156","author":"Caldwell","year":"2015","journal-title":"Endocrinology"},{"key":"10.1016\/j.cca.2016.11.010_bb0230","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.maturitas.2015.06.002","article-title":"Testosterone and breast cancer prevention","volume":"82","author":"Glaser","year":"2015","journal-title":"Maturitas"},{"key":"10.1016\/j.cca.2016.11.010_bb0235","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/BF03350782","article-title":"The pathogenesis of polycystic ovary syndrome: lessons from ovarian stimulation studies","volume":"21","author":"Barnes","year":"1998","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.cca.2016.11.010_bb0240","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1095\/biolreprod.108.072801","article-title":"Developmental programming: differential effects of prenatal testosterone and dihydrotestosterone on follicular recruitment, depletion of follicular reserve, and ovarian morphology in sheep","volume":"80","author":"Smith","year":"2009","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.cca.2016.11.010_bb0245","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jri.2004.01.010","article-title":"The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling","volume":"63","author":"Wood","year":"2004","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.cca.2016.11.010_bb0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jsbmb.2011.01.008","article-title":"Alterations of folliculogenesis in women with polycystic ovary syndrome","volume":"124","author":"Sander","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.cca.2016.11.010_bb0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0092-8674(01)00196-9","article-title":"Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein","volume":"104","author":"Seo","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.cca.2016.11.010_bb0260","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.1073\/pnas.92.23.10619","article-title":"Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome","volume":"92","author":"Zhang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cca.2016.11.010_bb0265","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1074\/jbc.M209527200","article-title":"Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17","volume":"278","author":"Pandey","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.11.010_bb0270","doi-asserted-by":"crossref","first-page":"13265","DOI":"10.1074\/jbc.M414673200","article-title":"Regulation of 17,20 lyase activity by cytochrome b5 and by serine phosphorylation of P450c17","volume":"280","author":"Pandey","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2016.11.010_bb0275","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1210\/jc.2004-1860","article-title":"Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome","volume":"90","author":"Wickenheisser","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.11.010_bb0280","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1210\/mend.11.7.9940","article-title":"Multiple orphan nuclear receptors converge to regulate rat P450c17 gene transcription: novel mechanisms for orphan nuclear receptor action","volume":"11","author":"Zhang","year":"1997","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0285","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1210\/mend.14.6.0469","article-title":"Novel role for the nuclear phosphoprotein SET in transcriptional activation of P450c17 and initiation of neurosteroidogenesis","volume":"14","author":"Compagnone","year":"2000","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1210\/me.2003-0090","article-title":"Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1","volume":"18","author":"Wickenheisser","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0295","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/09513590.2011.650760","article-title":"17-Hydroxysteroid dehydrogenase type 5 gene polymorphism (-71A\/G HSD17B5 SNP) and treatment with oral contraceptive pills in PCOS women without metabolic comorbidities","volume":"28","author":"Maier","year":"2012","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0300","first-page":"247","article-title":"Clinical inquiry: what therapies alleviate symptoms of polycystic ovary syndrome?","volume":"64","author":"Moreno","year":"2015","journal-title":"J. Fam. Pract."},{"key":"10.1016\/j.cca.2016.11.010_bb0305","first-page":"30","article-title":"Metabolic syndrome: polycystic ovary syndrome","volume":"435","author":"Mortada","year":"2015","journal-title":"FP Essent."},{"key":"10.1016\/j.cca.2016.11.010_bb0310","first-page":"1345","article-title":"Efficacy and safety of metformin or oral contraceptives, or both in polycystic ovary syndrome","volume":"11","author":"Yang","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.cca.2016.11.010_bb0315","first-page":"175","article-title":"Oral contraceptives in polycystic ovary syndrome","volume":"39","author":"Helvaci","year":"2014","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0320","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/09513590.2010.507283","article-title":"The impact of oral contraceptives and metformin on anti-Mullerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia","volume":"27","author":"Panidis","year":"2011","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.cca.2016.11.010_bb0325","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1210\/jc.2014-1135","article-title":"Body composition is improved during 12months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome","volume":"99","author":"Glintborg","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cca.2016.11.010_bb0330","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1292\/jvms.12-0366","article-title":"A potential therapeutic application of SET\/I2PP2A inhibitor OP449 for canine T-cell lymphoma","volume":"75","author":"Fujiwara","year":"2013","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.cca.2016.11.010_bb0335","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1292\/jvms.15-0193","article-title":"The therapeutic effects of SET\/I2PP2A inhibitors on canine melanoma","volume":"77","author":"Enjoji","year":"2015","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.cca.2016.11.010_bb0340","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.18632\/oncotarget.2127","article-title":"Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands","volume":"5","author":"De","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2016.11.010_bb0345","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4161\/cc.11.3.19057","article-title":"Mouse model for probing tumor suppressor activity of protein phosphatase 2A in diverse signaling pathways","volume":"11","author":"Walter","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cca.2016.11.010_bb0350","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2014.141","article-title":"Effect of FTY720 on the SET-PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity","volume":"28","author":"Pippa","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2016.11.010_bb0355","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/0008-5472.CAN-10-0999","article-title":"Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway","volume":"70","author":"Park","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2016.11.010_bb0360","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000341299","article-title":"The apolipoprotein-E-mimetic COG112 protects amyloid precursor protein intracellular domain-overexpressing animals from Alzheimer's disease-like pathological features","volume":"12","author":"Ghosal","year":"2013","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.cca.2016.11.010_bb0365","first-page":"388","article-title":"Regulation of PP2A by sphingolipid metabolism and signaling","volume":"4","author":"Oaks","year":"2014","journal-title":"Front. Oncol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898116304569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898116304569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T22:23:26Z","timestamp":1536272606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898116304569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":73,"alternative-id":["S0009898116304569"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2016.11.010","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologic significance of SET\/I2PP2A-mediated PP2A and non-PP2A pathways in polycystic ovary syndrome (PCOS)","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2016.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}